课题基金 / 基金详情

PERINATAL CORE PROTOCOL (PACTG P1025) (HIV)

PERINATAL CORE PROTOCOL (PACTG P1025) (HIV)
围产期核心方案 (PACTG P1025) (HIV)
批准号:
7603908
负责人:
ALICE STEK
金额:
$14.44万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-12-01 至 2007-11-30

项目摘要

项目成果

ALICE STEK的其他基金

相关文献

中文摘要
翻译
这个子项目是众多研究子项目之一
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To date, approximately 500-600 cases of vertical transmission of human immunodeficiency virus type 1 (HIV) occur annually in the United States. The dramatic reduction in vertical transmission rates in the United States is related to several factors, including: increased provision and acceptance of voluntary counseling and HIV testing of pregnant women, improvements in the medical management of HIV- infected pregnant women, and the development and increased acceptance of interventions to decrease the risk of mother-to-child transmission of HIV. Specific U.S public Health Service guidelines recommend antiretroviral therapy (ART) during pregnancy appropriate to maximize health of the women. However, data regarding the effectiveness and safety of and adherence to ART during pregnancy are limited. In addition, important questions remain unanswered regarding risk factors for vertical transmission and why interventions fail. and the safety of interventions for women and their infants.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PERINATAL CORE PROTOCOL (PACTG P1025) (HIV)
PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL THERAPY DURING PREGNANCY (PACTG)
A PHASE III, RANDOMIZED TRIAL OF THE SAFETY AND ANTIRETROVIRAL EFFECTS OF ZID
PERINATAL CORE PROTOCOL (PACTG P1025) (HIV)